Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat

Regulatory Peptides

Volumn 91, Issue 1-3, 2000, Pages 75-81

  Bojanowska, Ewa ^a   Stempniak, Bozena ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Neurohypophysis; Oxytocin; Vasopressin

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; OXYTOCIN; VASOPRESSIN;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; FEMALE; HYPOPHYSIS; MALE; NEUROHYPOPHYSIS; NEUROMODULATION; NONHUMAN; OXYTOCIN RELEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; VASOPRESSIN RELEASE;

ANIMALS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HYPERTENSION; INJECTIONS, INTRAVENOUS; MALE; NEUROTRANSMITTER AGENTS; OXYTOCIN; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; SEX FACTORS; TIME FACTORS; VASOPRESSINS;

EID: 0034725655     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(00)00119-1     Document Type: Article

References (33)

1. Renaud P., Bourque C.W. Neurophysiology and neuropharmacology of hypothalamic magnocellular neurons secreting vasopressin and oxytocin. Progress Neurobiol. 36:1990;131-169.
2. Share L. Control of vasopressin release: an old but continuing story. News Physiol. Sci. 11:1996;7-13.
3. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides - mediation of the actions of leptin. Trends Neurosci. 22:1999;62-67.
4. Ørskov C., Rabenhøj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentration of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 43:1994;535-539.
5. Fehmann H.-C., Göke R., Göke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 16:1995;390-410.
6. Holst J.J. Glucagon, glucagon-like peptide-1 and their receptors: an introduction. Acta Physiol. Scand. 157:1996;309-315.
7. Jin S.-L.C., Han V.K.M., Simmons J.G., Tawle A.G., Lauder J.M., Lund P.K. Distribution of glucagon-like peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J. Comp. Neurol. 271:1988;519-532.
8. Kreymann B., Ghatei M.A., Burnet P., Williams G., Kanse S., Diani A.R., Bloom S.R. Characterization of glucagon-like peptide-1-(7-36) amide in the hypothalamus. Brain Res. 502:1989;325-331.
9. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 137:1996;2968-2978.
10. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403:1999;261-280.
11. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 7:1995;2294-2300.
12. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the pituitary. Neuroendocrinology. 62:1995;130-134.
13. Navarro M., de Fonsceca F.R., Alvarez E., Chowen J.A., Zueco J.A., Gomez R., Eng J., Blazquez E. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J. Neurochem. 67:1996;1982-1991.
14. Shughrue P.J., Lane M.V., Merchenthaler I. Glucagon-like peptide-1 receptor (GLP-R) mRNA in the rat hypothalamus. Endocrinology. 37:1996;5159-5162.
15. Shalev A. The role of glucagon-like peptide 1 in the regulation of glucose homeostasis and satiety. Eur. J. Endocrinol. 137:1997;220-221.
16. Nauck M.A., Holst J.J., Willms B., Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp. Clin. Endocrinol. Diabetes. 105:1997;187-195.
17. Creutzfeldt W.O.C., Kleine N., Willms B., Ørskov C., Holst J.J., Nauck M.A. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type I diabetic patients. Diabetes Care. 19:1996;580-586.
18. Barragán J.M., Rodriguez R.E., Eng J., Blázquez E. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul. Peptides. 67:1996;63-68.
19. Barragán J.M., Rodriguez R.E., Blázquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am. J. Physiol. 29:1994;E459-E466.
20. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101:1998;515-520.
21. Gutzwiller J.-P., Drewe J., Göke B., Schmidt H., Rohrer B., Lareida J., Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276:1999;R1541-R1544.
22. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M.B., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P.H., Smith D.M., Ghatei M.A., Herbert J., Bloom S.R. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 379:1996;69-72.
23. Tang-Christensen M., Larsen P.J., Göke R., Fink-Jensen A., Jessop D.S., Møller M., Sheikh S.P. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 271:1996;R848-R856.
24. Larsen P.J., Tang-Christensen M., Jessop D.S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 138:1997;4445-4455.
25. Bojanowska E., Forsling M.J. The effects of melatonin on vasopressin secretion in vivo: interactions with acetylcholine and prostaglandins. Brain Res. Bull. 42:1997;457-461.
26. Bojanowska E., Guzek J.W., Dabrowski R. Luteinizing hormone-releasing hormone and function of the magnocellular vasopressinergic system. Neuropeptides. 33:1999;301-305.
27. Lewandowska A., Bojanowska E., Stempniak B., Guzek J.W. Luliberin inhibits the release of oxytocin from hypothalamo-neurohypophysial system in dehydrated but not in euhydrated or haemorrhaged rats. Endocr. Regul. 29:1995;225-231.
28. Barragán J.M., Eng J., Rodriguez R., Blázquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am. J. Physiol. 277:1999;E784-E791.
29. 131J-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl. Med. Biol. 26:1999;413-420.
30. Ørskov C., Poulsen S.S., Møller M., Holst J.J. Glucagon-like peptide 1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes. 45:1996;832-835.
31. Johnson A.K., Gross A.M. Sensory circumventricular organs and brain homeostasis pathways. FASEB J. 7:1993;678-686.
32. Zueco J.A., Esquifino A.I., Chowen J.A., Alvarez E., Castrillón P.O., Blázquez E. Coexpression of glucagon-like peptide-1 (GLP-1) receptor, vasopressin, and oxytocin mRNAs in neurons of the rat hypothalamic supraoptic and paraventricular nuclei: effect of GLP-1(7-36) amide on vasopressin and oxytocin release. J. Neurochem. 72:1999;10-16.
33. Van Dijk G., Thiele T.E., Donahey J.C.K., Campfield L.A., Smith F.J., Burn P., Bernstein I.L., Woods SC., Seeley R.J. Central infusions of leptin and GLP-1(7-36) amide differentially stimulate c-FLI in the rat brain. Am. J. Physiol. 40:(7-36):1996;R1096-R1100.